康柏西普联合曲安奈德治疗渗出型老年性黄斑变性的疗效观察

目的评估康柏西普眼用注射液联合小剂量曲安奈德注射液治疗渗出型老年性黄斑变性的临床疗效。方法选取2012年1月—2015年1月在咸阳市第一人民医院眼科就诊并住院治疗的74例渗出型老年性黄斑变性患者,共80只眼。将所有患者以就诊单双号为标准对患者进行分组,其中单号为对照组,双号为治疗组,每组各37例40只眼。对照组球内注射曲安奈德注射液,0.1 m L/次,1次/d。治疗组球内注射曲安奈德注射液减量至0.025 m L/次基础上球内注射康柏西普眼用注射液,0.05 m L/次,1次/月。两组均连续治疗3个月。观察两组视力改善和黄斑部荧光渗漏及遮蔽荧光改善的临床疗效,同时比较两组治疗前后与治疗后1、2、3个月黄斑中心凹视网膜厚度、最佳矫正视力、眼压值和生活质量评分。结果治疗3个月后,对照组和治疗组视力改善和黄斑部荧光渗漏及遮蔽荧光改善的总有效率分别为80.00%、95.00%,75.00%、92.50%,两组比较差异具有统计学意义(P0.05)。治疗3个月后两组黄斑中心凹视网膜厚度、最佳矫正视力、眼压值比较差异具有统计学意义(P0.01、0.05)。治疗后两组除读和精细工作外其他各项指标均有明显变化(P0.05、0.01);治疗组第1、2、3个月远视力等、调节能力、读和精细工作、日常生活能力评分均显著高于对照组(P0.05)。结论康柏西普眼用注射液联合小剂量曲安奈德注射液治疗渗出型老年性黄斑变性具有较好的临床效果,能有效改善患者视功能,提升生活质量,且不良反应少,安全性较高,具有一定的临床推广应用价值。

Clinical observation of conbercept combined with triamcinolone acetonide in treatment of exudative age-related macular degeneration

Objective To evaluate the clinical efficacy of Conbercept Ophthalmic Injection combined with Triamcinolone Acetonide Injection in treatment of exudative age-related macular degeneration (AMD). Methods Patients (74 cases, 80 eyes) with exudative AMD in Department of Ophthalmology of The First People's Hospital of Xianyang City from January 2012 to January 2015 were divided into control and treatment groups according to the visiting single or even numbers, and each group had 37 cases or 40 eyes. The patients in the control group were intraocular injection administered with Triamcinolone Acetonide Injection, 0.1 mL/time, once daily. The patients in the treatment group were intraocular injected with Conbercept Ophthalmic Injection on the basis of control group with Triamcinolone Acetonide Injection 0.025 mL/time, 0.05 mL/time, once monthly. The patients in two groups were treated for 3 months. After treatment, the clinical efficacies of vision improvement and improvement of fluorescence leakage and shading in the macular were evaluated. And thickness of the retina, the best corrected visual acuity, intraocular pressure, quality of life in two groups before treatment and after treatment for 1, 2, and 3 months were compared. Results After treatment, the efficacy of vision improvement and improvement of fluorescence leakage and shading in the macular in the control and treatment groups were 80.00%, 95.00%, 75.00%, and 92.50%, respectively, and there were differences between two groups (P < 0.05). After treatment for 3 months, thickness of the retina and the best corrected visual acuity in the treatment group were significantly better than those in the control group, with significant difference between two groups (P < 0.01). But there was no significant difference on intraocular pressure between two groups. After treatment, quality of life indexes except reading and fine work in two groups had obvious changes, and the difference was statistically significant in the same group (P < 0.05, 0.01). After treatment in the 1^st, 2nd, and 3rd month, distant visual acuity, adjustment ability, reading and fine work, and daily life ability score in the treatment group were higher than those in the control group (P < 0.05). Conclusion Conbercept Ophthalmic Injection combined with Triamcinolone Acetonide Injection has clinical curative effect in the treatment of AMD, can effectively improve the visual function, improve the quality of life, and less adverse reaction, high security, which has a certain clinical application value.